Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
2.51    -0.19 (-7.04%)
Bid:
2.50
Ask:
2.70
Spread: 0.20 (8.00%)
Market Cap: £2.59m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

Case Investment Settlement Update

20 Dec 2019 08:04

RNS Number : 6210X
Litigation Capital Management Ltd
20 December 2019
 

20 December 2019

Litigation Capital Management Limited

("LCM" or the "Company")

 

Case Investment Settlement Update

 

Litigation Capital Management Limited (AIM:LIT), a leading international provider of litigation financing solutions, announces the resolution of two single-case investments:

 

The first is the resolution of a claim which was pursued in the Supreme Court of Queensland in Australia. The claim has been resolved through negotiation. The resolution will generate revenue to LCM this financial period of approximately A$6.45m, and contribution to gross profit of approximately A$2m.

 

The second is the resolution of a claim which was pursued in the Supreme Court of New South Wales in Australia. That claim also resolved through negotiation. The resolution of that investment will generate revenue of approximately A$4m, and contribution to gross profit of not less than A$2.5m.

 

The funds from the above resolutions will be received during the current financial year.

 

Patrick Moloney, CEO of LCM said: "We are pleased to update the market with the resolution of these two single-case investments. Single-case investments have been a fundamental part of our stringent business model since LCM's inception and the settlement of these respective disputes reinforces the ongoing opportunity and demand for investment in such cases.

 

"Our robust investment strategy remains a core part of our model and demonstrates the large and diverse investment opportunities within the Company."

 

CONTACTS

 

Litigation Capital Management

c/o Alma PR 

Patrick Moloney, Chief Executive Officer

 

 

Canaccord (Nomad and Joint Broker) 

Tel: 020 7523 8000

Bobbie Hilliam

 

 

 

Investec Bank plc (Joint Broker)

Tel: 020 7597 5970

David Anderson

 

 

Alma PR

Tel: 020 3405 0205

Rebecca Sanders-Hewett

LCM@almapr.co.uk

Justine James

 

Susie Hudson

 

Jessica Joynson

 

 

NOTES TO EDITORS

 

About LCM:

 

Litigation Capital Management ("LCM") is a leading international provider of litigation financing solutions. This includes single-case and portfolios across; class actions, commercial claims, claims arising out of insolvency and international arbitration. LCM has an unparalleled track record, driven by effective project selection, active project management and robust risk management.

 

Headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

 

LCM Investment Strategies

 

LCM operates three principal investment strategies:

 

Single-case strategy - involves investing in single disputes.

 

Acquisition strategy - involves the acquisition or taking an assignment of causes of action. LCM pursues that strategy by acquiring the dispute and pursues it as principal.

 

Portfolio funding - involves LCM providing a financing and risk management solution to large and sophisticated corporate clients, which will include a number of cases at any given time. Portfolio funding is a relatively new strategy to the industry and LCM leads the market in this space.

 

www.lcmfinance.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFEESASFUSESE
Date   Source Headline
1st Jun 20267:00 amRNSUpdate on Covenant Waiver, Case & Strategic Review
15th Apr 20267:30 amRNSCovenant Waiver Extension
31st Mar 20267:00 amRNSInterim results for the HY ended 31 December 2025
25th Mar 20267:00 amRNSNotice of H1 Results, Trading update and IMC
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
11th Mar 20269:34 amRNSUpdate on Case Investment and Strategic Review
2nd Mar 20267:00 amRNSCovenant Waiver Extension
2nd Feb 20267:00 amRNSIncrease in Credit Facility and Waiver Extension
12th Jan 20262:07 pmRNSPositive development on case
30th Dec 20257:00 amRNSCovenant Waiver Extension
30th Dec 20257:00 amRNSCovenant Waiver Extension
24th Dec 20257:00 amRNSAdverse Costs Order in Class Action Investment
27th Nov 20251:08 pmRNSResults of AGM
26th Nov 20255:00 pmRNSStrategic Review Update
19th Nov 202511:54 amRNSPosting of Annual Report and Accounts
4th Nov 20252:29 pmRNSNotice of Annual General Meeting
21st Oct 202511:37 amRNSPostponement of Annual General Meeting
13th Oct 202511:39 amRNSExercise of Awards
6th Oct 20257:00 amRNSUpdate on Commercial Arbitration Loss
2nd Oct 20258:40 amRNSTR-1
1st Oct 20254:49 pmRNSNotice of Annual General Meeting
1st Oct 202511:25 amRNSJudgment Delivered in Commercial Litigation Claim
1st Oct 20257:00 amRNSAnnual Results for the year ended 30 June 2025
15th Sep 20257:00 amRNSClass Action Investment and Strategic Review
8th Sep 20257:00 amRNSNotice of Results
23rd Jun 20259:45 amRNSTR - 1
19th Jun 20257:00 amRNSJudgment in Funded Case and Trading Update
13th May 20252:50 pmRNSStatement Regarding Media Speculation
1st Apr 20257:00 amRNSOutcome of Commercial Arbitration Investment
18th Mar 20257:00 amRNSInterim results for the HY ended 31 December 2024
7th Mar 20252:54 pmRNS-RInvestor Presentation via Investor Meet Company
28th Feb 20257:00 amRNSAppeal Filed in Class Action Investment
21st Feb 20257:00 amRNSJudgment Delivered in Class Action Investment
4th Feb 20258:33 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSTrading Update
15th Jan 202511:14 amRNSHolding(s) in Company
19th Dec 20247:00 amRNSDirectorate Change
6th Dec 202411:15 amRNSHolding(s) in Company
6th Dec 20247:00 amRNSAppointment of CFO to the Board of Directors
4th Dec 20247:00 amRNSJudgment Delivered in Class Action Investment
2nd Dec 20247:00 amRNSNew Credit Facility
15th Nov 20247:00 amRNSDirector/PDMR Shareholding
8th Nov 20247:06 amRNSHolding(s) in Company
8th Nov 20247:00 amRNSTransaction in Own Shares
7th Nov 20247:00 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
5th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.